NO20080877L - Fremgangsmater for behandling av substansrelaterte forstyrrelser - Google Patents

Fremgangsmater for behandling av substansrelaterte forstyrrelser

Info

Publication number
NO20080877L
NO20080877L NO20080877A NO20080877A NO20080877L NO 20080877 L NO20080877 L NO 20080877L NO 20080877 A NO20080877 A NO 20080877A NO 20080877 A NO20080877 A NO 20080877A NO 20080877 L NO20080877 L NO 20080877L
Authority
NO
Norway
Prior art keywords
sub
phenyl
alkyl
group
methods
Prior art date
Application number
NO20080877A
Other languages
English (en)
Inventor
Carlos R Plata-Salaman
Boyu Zhao
Roy E Twymman
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20080877L publication Critical patent/NO20080877L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives en metode for en prevensjon, terapi eller lindring av substansrelaterte forstyrrelser hos et individ, omfattende administrering til individet av en effektiv mengde av en forbindelse valgt blant: eller farmasøytisk akseptable former derav, hvor substituentene er som definert i søknaden. I tillegg beskrives det metoder som involverer koadministrering av forbindelser ifølge oppfinnelsen med en eller flere forbindelser kjent for å behandle substansinduserte forstyrrelser.
NO20080877A 2005-07-26 2008-02-19 Fremgangsmater for behandling av substansrelaterte forstyrrelser NO20080877L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (1)

Publication Number Publication Date
NO20080877L true NO20080877L (no) 2008-02-19

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080877A NO20080877L (no) 2005-07-26 2008-02-19 Fremgangsmater for behandling av substansrelaterte forstyrrelser

Country Status (13)

Country Link
EP (1) EP1928451B1 (no)
JP (1) JP5094720B2 (no)
KR (1) KR101199499B1 (no)
CN (1) CN101272776B (no)
AT (1) ATE538784T1 (no)
AU (1) AU2005335241B9 (no)
BR (1) BRPI0520451A2 (no)
CA (1) CA2616721C (no)
EA (1) EA019935B1 (no)
ES (1) ES2385087T3 (no)
IL (1) IL189003A0 (no)
NO (1) NO20080877L (no)
WO (1) WO2007018496A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
IN2012DN00624A (no) 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
DK2968208T3 (da) 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi
JP6529495B2 (ja) 2013-07-18 2019-06-12 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 肥満の治療
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
WO2018222954A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals International Iii Limited Methods and compositions for treating excessive sleepiness
WO2020262317A1 (ja) * 2019-06-27 2020-12-30 Ｎｕｍａｎ Ｌａｂｏ合同会社 認知症の治療及び予防薬
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
AU2002242226B2 (en) * 2001-02-27 2006-06-29 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
RS51056B (sr) * 2001-02-27 2010-10-31 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja
MXPA03007718A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para usarse en la prevencion o tratamiento de trastornos neurodegenerativos.
NZ551954A (en) * 2001-02-27 2008-07-31 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating movement disorders
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
WO2007018496A1 (en) 2007-02-15
AU2005335241A1 (en) 2007-02-15
BRPI0520451A2 (pt) 2009-05-12
ES2385087T3 (es) 2012-07-18
EA200800422A1 (ru) 2008-10-30
JP5094720B2 (ja) 2012-12-12
AU2005335241B2 (en) 2012-11-15
EP1928451B1 (en) 2011-12-28
JP2009502914A (ja) 2009-01-29
ATE538784T1 (de) 2012-01-15
CN101272776A (zh) 2008-09-24
EA019935B1 (ru) 2014-07-30
CN101272776B (zh) 2012-10-03
EP1928451A1 (en) 2008-06-11
CA2616721A1 (en) 2007-02-15
AU2005335241B9 (en) 2012-12-20
CA2616721C (en) 2014-01-21
KR101199499B1 (ko) 2012-11-09
KR20080037055A (ko) 2008-04-29
IL189003A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
WO2007008562A3 (en) Carbamate compounds for use in treating neurodegenerative disorders
TW200744575A (en) Methods of treating epileptogenesis
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
RS67403A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
PT1408953E (pt) Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar
NO20033800L (no) Karbamidforbindelser for bruk ved prevensjon eller terapi av angstlidelser
WO2008060787A3 (en) Methods for treatment of cochlear and vestibular disorders
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
MY149385A (en) Methods for treating substance-related disorders
NO20040176L (no) Karbamatforbindelser for anvendelse ved prevensjon eller terapi av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
TW200701978A (en) Methods of treating epileptogenesis and epilepsy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application